BMI1 and diffuse large B-cell lymphoma: Cell viability was determined in seven AML cell lines and one BCL2-driven DLBCL cell line treated with increasing dosages of single compounds and in combination using a variety of targeted therapies including the BCL-XL inhibitor A1331825, the PI3K inhibitor bimiralisib (PCR309), the STAT3 inhibitor C-188-9, the BMI-1 inhibitor PTC596, the MCL1 inhibitor S63845, and the MEK inhibitor trametinib.